Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
NovoCure Ltd. (NVCR) PT Raised to $44 at Mizuho Securities
July 27, 2018 8:44 AM EDTMizuho Securities raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $44.00 (from $32.00) while maintaining a Buy rating.
Analyst Difei Yang commented, "NovoCure reported 2Q18 results yesterday. Net revenue of $61.5 mil beat FactSet consensus of $59.5 mil while EPS of $(0.17) was slightly below consensus of... More
Novocure (NVCR) Misses Q2 EPS by 1c, Revenues Beat
July 26, 2018 6:17 AM EDTNovocure (NASDAQ: NVCR) reported Q2 EPS of ($0.17), $0.01 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $61.5 million versus the consensus estimate of $59.52 million.
In the second quarter of 2018, Novocure demonstrated continued commercial momentum for Optune and continued progress on key clinical development programs, noted Asaf Danziger, Novocures Chief Executive Officer. We delivered record quarterly revenue of $61.5 million, up 60 percent from the second quarter 2017 and 18... More
